Enough beds, ventilators for Covid patients in govt hospitals: Health Min

Health workers wearing personal protective equipment (PPE) during a rapid antigen testing for coronavirus disease at Kalupur railway station premises in Ahmedabad on Monday.

Sufficient number of beds and ventilators for coronavirus infected patients were available after March 24 in AIIMS and other central government-run hospitals of the country, Ministerof State for Health Ashwini Choubey told the Lok Sabha on Friday.

The minister replied in the negative to a question on whether an increase in deaths of patients has been registered due to insufficient beds and ventilators in hospitals.

There were 1,707 beds and 292 ventilators in March which have been increased to7,403 beds and 906 ventilators in September in the Health Ministry's 13 COVID dedicated hospitals in the country, Choubey said.

Providing data on the number of pathological labs available across the country for conducting COVID-19 tests in response to a question, Choubey said the Indian Council of Medical Research (ICMR), an autonomous organisation under the Department of Health Research, has informed that as on September 13, a total of 1,717 COVID-19 testing laboratories are registered on its portal comprising 1,049 government labs and 668 private labs.

In addition, ICMR has a total of 5,134 antigen testing sites in their database as on September 17, he said.

"The ICMR has informed that till September 13, a total 5,72,39,428 COVID-19 tests have been performed by the testing laboratories, of which 48,46,427 have been reported as COVID-19 infected," the minister said.

He also stated that ICMR has informed that it is in the process of on-boarding more new labs through its 14 mentor institutes.

Private and government medical institutions that have not yet set-up a lab have been issued instructions to expedite the process for the same. According to ICMR, there are more than 250 labs which are in the process of setting-up COVID-19 testing facilities, the minister said.

Further, in response to another question, the minister informed that India's testing strategy includes rapid antigen test for fast detection of COVID-19 infected patients.

Rapid antibody tests can be used for detecting the presence of antibodies in recovered individuals. These are not used for patient diagnosis, he said.

The ICMR has informed that it has been interacting with national and international manufacturers who have expressed their interest in supplying diagnostics to India. The kit manufacturers are required to submit their product for validation at the designated centres of ICMR.

"Only the approved kits are provided marketing permission by the Drugs Controller General of India. However, US-FDA approved kits are exempted from validation.

"Price of procurement is based on a competitive tendering process. ICMR's validation process is based on standardized protocols developed under consultation of experts and are in line with global standards," he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel